Insider Selling: Vaxcyte (NASDAQ:PCVX) EVP Sells $137,025.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.90, for a total transaction of $137,025.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total transaction of $1,561,320.00.
• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.67, for a total transaction of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.

Vaxcyte Price Performance

PCVX stock opened at $63.89 on Friday. The company’s 50-day moving average price is $61.71 and its two-hundred day moving average price is $57.32. Vaxcyte, Inc. has a 12 month low of $40.14 and a 12 month high of $90.75.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter in the prior year, the business posted ($1.56) EPS. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on PCVX shares. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Guggenheim boosted their price target on Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, October 5th. BTIG Research reissued a “buy” rating and issued a $89.00 price target on shares of Vaxcyte in a report on Monday, October 5th. Bank of America decreased their target price on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. Finally, Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vaxcyte presently has an average rating of “Moderate Buy” and a consensus price target of $110.50.

Institutional Trading of Vaxcyte

Several hedge funds have recently bought and sold shares of PCVX. Jupiter Topco LLC bought a new stake in shares of Vaxcyte in the second quarter worth approximately $1,044,355,000. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.8% during the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after buying an additional 3,188,687 shares during the period. BlackRock Inc. bought a new position in shares of Vaxcyte during the 2nd quarter valued at about $701,520,000. Wellington Management Group LLP boosted its holdings in Vaxcyte by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock valued at $407,001,000 after purchasing an additional 1,386,968 shares during the period. Finally, Jennison Associates LLC boosted its holdings in Vaxcyte by 150.6% during the first quarter. Jennison Associates LLC now owns 1,698,011 shares of the company’s stock worth $98,671,000 after buying an additional 1,020,458 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.